Miralax
ApprovedSmall molecule
FerringMiralax is one of 29 small molecule programs targeting Constipation. It is currently in Approved.
2
Indications
9
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
132 competitors in Hysterectomy
#DrugCompanyPhaseTrials
1Arcoxia
NovartisPhase 3
Cervidil
PfizerPhase 3
Elavil
AstraZenecaPhase 3
Tylenol
KKenvue Brands
Phase 3
Epsom Salt
FFresenius Kabi Oncology Ltd.
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Dilaudid
RRhodes Pharmaceuticals, L.P.
Phase 3
Ketalar
AAultman Health Foundation
Phase 3
Miralax
FerringApproved
Spravato
WWim Janssens
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bowel Preparation4 trials
A Study Comparing PEG-3350 (Miralax) and Gatorade With PEG-ELS (Golytely) for Bowel Preparation Prior to Colonoscopy
Unknown status·SSouthern California Institute for Research and Education·N/A·NCT01028573·400 enrolled
Show 1 more trial
Colonoscopy1 trial
A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy
Completed·—·Phase 4·NCT00953017·425 enrolled
Hysterectomy1 trial
Constipation1 trial
MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery
Completed·—·N/A·NCT01691742·131 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Miralax. EMBL-EBI & Wellcome Sanger Institute.
- [4]